Printer Friendly

SYNAPTIC PHARMACEUTICAL FILES FOR INITIAL PUBLIC OFFERING OF COMMON STOCK; NAME CHANGED FROM NEUROGENETIC CORPORATION

       SYNAPTIC PHARMACEUTICAL FILES FOR INITIAL PUBLIC OFFERING
      OF COMMON STOCK; NAME CHANGED FROM NEUROGENETIC CORPORATION
    PARAMUS, N.J., March 12 /PRNewswire/ -- Synaptic Pharmaceutical Corporation (formerly Neurogenetic Corporation) announced the filing of a registration statement yesterday with the Securities and Exchange Commission relating to the proposed initial public offering of 2.5 million shares of common stock.  It is anticipated that the initial public offering price will be between $10 and $12 per share.
    Oppenheimer & Co., Inc. and Prudential Securities Incorporated will manage the offering.
    The company plans to use the proceeds from the offering for research and product development activities, including pre-clinical testing, clinical trials, leasehold improvements and general corporate purposes.
    The company's new name reflects its distinct focus on developing drugs that act at the synapse, the key site of signal transmission within the nervous system.
    Synaptic Pharmaceutical Corporation, founded in 1987, has developed and is using a proprietary enabling technology to develop drugs that modulate the functioning of the nervous system.  The company believes that this technology will enable it to develop drugs that will be more effective and have fewer side effects than existing drugs.  The company, independently or in collaboration with others, is designing drugs for the treatment of psychiatric and physiological disorders that have historically been difficult to manage, such as depression, anxiety, migraine headache and urinary symptoms of benign prostatic hyperplasia (enlarged prostate), and intends to develop new types of anesthetics, analgesics and sedatives.
    A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective.  These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
    -0-            3/12/92
    /CONTACT:  Thomas A. Pearson of Pearson Communications, 215-648-3975, for Synaptic Pharmaceutical/ CO:  Synaptic Pharmaceutical Corporation; Neurogenetic Corp. ST:  New Jersey IN:  MTC SU:  OFR PS -- NY082 -- 7594 03/12/92 17:50 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 12, 1992
Words:373
Previous Article:NEW YORK STOCK EXCHANGE CLOSING, THURSDAY, MARCH 12 /PRN/
Next Article:MEI DIVERSIFIED REPORTS FOURTH QUARTER RESULTS
Topics:


Related Articles
DR. TAUNTON-RIGBY ELECTED SYNAPTIC PHARMACEUTICAL DIRECTOR
TEXAS BIOTECHNOLOGY FILES FOR INITIAL PUBLIC OFFERING
SYNAPTIC PHARMACEUTICAL CLOSES INITIAL PUBLIC OFFERING OF 2 MILLION SHARES
Synaptic Pharmaceutical Reports Third Quarter And Nine Month Results
Synaptic Pharmaceutical Awarded Patent for Neuropeptide Y Feeding Receptor
Synaptic Pharmaceutical Files Registration Statement for Secondary Offering
Advancis Pharmaceutical Corporation Files with SEC for IPO.
Memory Pharmaceuticals Corp. Files Registration Statement For Initial Public Offering of Common Stock.
Pharmion Corporation Announces Initial Public Offering of Common Stock.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters